Boston Scientific cuts outlook after cyberattack impacts operations
Boston Scientific lowered its full-year sales outlook to $5.45-5.55 billion from $5.44-5.64 billion and cut adjusted EPS guidance after a cyberattack disrupted operations, sending shares down.
